The digital world is an integral part of global society, and the online traffic to psychedelic resources can tell us a lot about the state of...
Numinus has announced an at-the-market equity offering program that allows the company to issue and sell up to $10,000,000 (CAD) of common shares. The...
The Daily Hit is a recap of the top financial news stories for Sept. 27, 2023. On the Site SAFER Banking Act Approved by Senate Committee...
Psychedelic stocks are on the rise. Despite the stigma surrounding psychedelics for personal use, controlled medical experiments indicate their usefulness...
The study found that 100 per cent of patients were responsive and 92 per cent went into remission The post Antidepressants enhance DMT efficacy in patients...
The FDA has accepted the company’s Abbreviated New Drug Application for KETARX™ (racemic ketamine). The goal date for this priority original ANDA of...
The DMT drug appeared more effective when combined with SSRIs. The post Small Pharma Sees Promise Pairing DMT Drug with Antidepressants appeared first...
The exact number of shares to be sold will be determined by Numinus' financier. The post Numinus to Sell C$10M Worth of New Shares Through Equity...
Topline results from Small Pharma's Phase Ib study exploring the interaction between SSRIs and SPL026, the company’s DMT drug. The post Positive Data...
Efficacy Chart Efficacy results in both cohorts at baseline and at Week 4 following the dose of SPL026 with support therapy • Results...